Health sciences unit launched
LGC has launched a new business unit, Health Sciences, which combines the group?s sport, food, consumer safety and pharmaceutical testing activities within a single entity.
LGC has launched a new business unit, Health Sciences, which combines the group’s sport, food, consumer safety and pharmaceutical testing activities within a single entity. The unit offers supplement customers in-house testing from banned substances to additives/compositional testing.
The launch follows LGC’s acquisition of drug surveillance, doping control and research company, HFL Sport Science in December 2010. This acquisition extended and complemented the company’s analytical service offerings allowing the companies to provide a testing programme for foodstuffs, ingredients and nutritional supplements.
David Hall, CEO of HFL Sport Science and director of Health Sciences at LGC, commented: “By bringing together the knowledge, expertise and instrumentation of LGC and HFL into a single new business entity called Health Sciences we believe that this will bring significant benefit to our customers. In addition, this will open up a range of market opportunities in the UK, Europe and the USA.”
The new unit’s range of testing services include banned substances (prohibited by the World Anti-Doping Agency); nutritional biomarkers; nutritional analysis; and contaminants and residues.
For more information visit www.lgc.co.uk
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
